20.10SEK-1.95%Mkt Cap: 706.05M SEKP/E: —Last update: 2026-06-01
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products in…
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap706.05M SEK
Enterprise Value340.89M SEK
Revenue (TTM)17.80M SEK
Gross Profit11.50M SEK
Net Income (TTM)639.30M SEK
Revenue/Share0.5120 SEK
Last Price20.10 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees65
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.79
PEG13.07
EV/EBITDA-1.12
EV/Revenue19.15
P/S40.46
P/B1.97
EPS (TTM)-12.02
EPS (Forward)-4.28
52W Range
14.3820% of range43.40
52W High43.40 SEK
52W Low14.38 SEK
Profitability
Gross Margin44.23%
Oper. Margin-1514.00%
EBITDA Margin0.00%
Profit Margin2458.85%
ROE130.31%
ROA49.07%
Growth
Revenue Growth-62.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-195.40M SEK
CapEx (TTM)—
FCF Margin-0.84%
FCF Yield-0.02%
Net Debt-379.20M SEK
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity1.00
Current Ratio2.02
Quick Ratio1.97
Book Value/Sh10.38 SEK
Cash/Share10.99 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)29.00 SEK
Target Range29.00 SEK – 29.00 SEK
# Analysts1
Ownership
Shares Out.35.13M
Float21.45M
Insiders18.89%
Institutions40.28%
Technical
SMA 5020.32 (-1.1%)
SMA 20026.38 (-23.8%)
Beta0.87
S&P 52W Chg27.70%
Avg Vol (30d)48.14K
Avg Vol (10d)53.68K
Technical Indicators
RSI (14)53.9
MACD0.1191
MACD Signal-0.2630
MACD Hist.+0.3821
BB Upper21.48 SEK
BB Middle19.31 SEK
BB Lower17.14 SEK
BB Width22.50%
ATR (14)1.165 SEK
Vol Ratio (20d)0.42x